Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy.

Frontiers in immunology - 1 Jan 2021

DeRogatis Julia M, Viramontes Karla M, Neubert Emily N, Tinoco Roberto

Abstract excerpt

Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkpoints have shown promise in promoting anti-tumor immunity. PSGL-1, primarily known for its role in cellular migration, has also been shown to function as a negative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphocytes, Tumor-Infiltrating

Share to Membrane Glycoproteins

Share to Mice, Knockout

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33708224
DOI: 10.3389/fimmu.2021.636238
PMCID: PMC7940186

Genes

CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy.PMID 33708224Read ↗

Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancerSemantic proximity Read ↗

PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanomaSemantic proximity Read ↗

PSGL-1 directs early TCR signaling to repress metabolism and promote T cell exhaustion by modulating the TCF-1/TOX axis in CD8 <sup>+</sup> T cellsSemantic proximity Read ↗

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapySemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Emerging concepts in PD-1 checkpoint biologySemantic proximity Read ↗

Contrasting roles of PSGL-1 and PD-1 in regulating T-cell exhaustion and function during chronic viral infectionSemantic proximity Read ↗

The ITPRIPL1- CD3ε axis: a novel immune checkpoint controlling T cells activationSemantic proximity Read ↗

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and TherapySemantic proximity Read ↗

KLRG1 identifies circulating cytotoxic CD4 T cells with selective anti-tumor function in human cancerSemantic proximity Read ↗

SIGLEC1 FACILITATES MACROPHAGE-CD8 <sup>+</sup> T CELL INTERACTIONS AND CORRELATES WITH CANCER IMMUNOTHERAPY RESPONSESemantic proximity Read ↗

Immune checkpoint signaling and cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.